1. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection

2. Overview

3. Increase in Proportionate CVD Mortality Rates in the HIV-Infected Population Since 1999, While Declining in Others

4. Why Has CVD Mortality Increased Among HIV-Infected Persons?

5. Assessment of CVD Risk in Patients With HIV Infection

6. Viral and ART Factors Contribute to Increased VLDL and Decreased HDL Levels

7. Importance of Statins in Patients With HIV Infection: Beyond LDL-C Reduction?

8. Role for Statins in Patients With HIV Infection

9. Mean Changes in Blood Lipids for 50 Seroconverters Initiating HAART

10. Contemporary ART: More Lipid Neutral

11. Assessment of CV Risk in the HIV-Infected Patient

12. Atorvastatin Effects on ASCVD Progression in HIV Infection Reduced Plaque Progression vs Placebo

13. Rosuvastatin Effects on CCA-IMT in HIV Infection: Reduced Carotid IMT Progression vs Placebo -- SATURN Trial

14. Use of Statins With Protease Inhibitors

15. Lifestyle and Pharmacologic Modification of Nonlipid CVD Risk Factors

16. REPRIEVE Trial Design

17. REPRIEVE Trial Hypotheses

18. Why Pitavastatin in REPRIEVE?

19. Concluding Remarks

20. Abbreviations

21. Abbreviations (cont)